MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,084 | +12.3% | 206 | +77.6% | 0.00% | – |
| Q2 2023 | $26,796 | +46910.5% | 116 | -50.8% | 0.00% | – |
| Q1 2023 | $57 | +103.6% | 236 | +145.8% | 0.00% | – |
| Q4 2022 | $28 | -99.6% | 96 | 0.0% | 0.00% | – |
| Q3 2022 | $7,000 | -53.3% | 96 | -54.9% | 0.00% | – |
| Q2 2022 | $15,000 | -53.1% | 213 | -35.1% | 0.00% | – |
| Q1 2022 | $32,000 | -68.6% | 328 | -81.5% | 0.00% | -100.0% |
| Q4 2021 | $102,000 | -55.1% | 1,775 | -37.5% | 0.00% | 0.0% |
| Q3 2021 | $227,000 | -18.1% | 2,842 | -0.1% | 0.00% | -50.0% |
| Q2 2021 | $277,000 | -24.7% | 2,845 | -9.5% | 0.00% | 0.0% |
| Q1 2021 | $368,000 | +5.1% | 3,145 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $350,000 | +22.0% | 3,145 | +30.1% | 0.00% | 0.0% |
| Q3 2020 | $287,000 | -40.8% | 2,417 | -43.5% | 0.00% | -50.0% |
| Q2 2020 | $485,000 | – | 4,281 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |